Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-15

Clinical Trial Update: Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the effect of glycopyrronium on morning COPD symptoms and pulmonary function; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • glycopyrronium (glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 4 | Status: COMPLETED | Results posted: 2016-04-15